GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: ACT451840 | Actelion-451840
                                 
                                                         
                            
                            
                            
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: ACT-451840 is an investigational antimalarial drug, selected from a new class of compounds identified from a phenotypic screen [2,4]. Chemically it is a piperazine-containing compound.  
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                      
                                     
                                   
                                   
                                    
                                    
                                    The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.  | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| No information available. | 
Summary of Clinical Use ![]()  | 
                                                        
| ACT-451840 has completed Phase 1 clinical trial in healthy subjects with induced blood stage malaria infection (see NCT02223871) [3,6]. A single 500 mg dose of the drug significantly reduced P. falciparum parasitaemia and cure was achieved in 90% of subjects with six once daily doses of 300 mg [6]. | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT02223871 | Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects | Phase 1 Interventional | Idorsia Pharmaceuticals Ltd. | ||
Pharmacokinetics ![]()  | 
                                                        
| Elimination | 
| ACT-451840 has a half-life of approximately 34 hours [3]. |